SYBX synlogictx.com: Koefisien utang jangka dawa marang modal

Synlogic, Inc. demonstrates high resilience to market cycles due to the demand for innovative medicine. Demand for the therapy of congenital metabolic disorders is independent of economic conditions, ensuring macro-stability. On GURU.Markets, long-term loans relative to equity visualize financial leverage, where 0.00 shows the value of this parameter. The issuer's stability currently relies on the success of its scientific platform in the absence of regular revenue.

This ratio compares long-term credit obligations to total equity to assess financial stability. By analyzing the long-term debt-to-equity history, an investor determines the extent of the company's reliance on external borrowings. A low metric level minimizes bankruptcy risk but may indicate an underutilization of growth levers. For Synlogic, Inc. (SYBX), this is critical, as a narrow specialization in metabolic diseases makes the business vulnerable. Stability of liabilities here serves as the sole buffer during the risky clinical validation of technologies.